Latest News for SDZNY
Stock rose 6.4% after the company bumped up its revenue guidance thanks to growth in its biosimilar product range.
Sandoz Group AG (SDZNY) Q4 2025 Earnings Call Transcript
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Sandoz Group AG Sponsored ADR (SDZNY).
Sandoz delivered steady revenue and EBITDA growth, with 2025 revenue projected near $11B and EBITDA margin guidance raised to 21-22%. SDZNY now trades at a relatively rich EV/EBITDA multiple of ~16 for 2025 and ~13 forward based on 2027 consensus estimates. While the business model and growth profile remain attractive, current valuation justifies only a "hold" rating after a 65% share price run-up.
Sandoz Group (OTCMKTS:SDZNY - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk. Institutional and Insider Ownership 0.1% of Sandoz Group
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SDZNY.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.